BRINEURA

This brand name is authorized in Austria, Brazil, Canada, Croatia, Estonia, Ireland, Japan, Lithuania, Netherlands, Poland, Romania, UK.

Active ingredients

The drug BRINEURA contains one active pharmaceutical ingredient (API):

1	Cerliponase alfa UNII X8R2D92QP1 - CERLIPONASE ALFA
	Cerliponase alfa is a recombinant form of human tripeptidyl peptidase-1 (rhTPP1). Cerliponase alfa is a proteolytic inactive proenzyme (zymogen) that is activated in the lysosome. The glycosylation profile of cerliponase alfa results in consistent cellular uptake and lysosomal targeting for activation.
	Read more about Cerliponase alfa

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BRINEURA Solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AB17		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AB Enzymes
Discover more medicines within A16AB17

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	542418120000201
CA	Health Products and Food Branch	02484013
EE	Ravimiamet	1746547
GB	Medicines & Healthcare Products Regulatory Agency	358138
JP	医薬品医療機器総合機構	3959422A1028
LT	Valstybinė vaistų kontrolės tarnyba	1083032
NL	Z-Index G-Standaard, PRK	148946
PL	Rejestru Produktów Leczniczych	100396302
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64486001